Evaluation of the therapeutic efficacy of the dextromethorphan–bupropion combination and its mediating pathways in a mouse model of major depressive disorder
Frontiers in Pharmacology August 19, 2026 İlay Buran Kavuran, Ebru Önalan, Zeliha İrem Türk et al.
Background Major depressive disorder (MDD) is associated with multiple pathophysiological mechanisms, including dysregulation of monoaminergic systems, excessive glutamatergic activity, reduced neurotrophic support, inflammation, and oxidative stress. The combination of dextromethorphan, an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, a...